REGENXBIO reported Q3 2026 results and confirmed its RGX-202 gene therapy for Duchenne muscular dystrophy is on track for a Biologics License Application (BLA) submission in Q1 2027, aiming for accelerated approval in the second half of 2027. The company also expects topline data from pivotal wet AMD trials in Q4 2026 and continues progress on diabetic retinopathy and other gene therapy programs. Financially, REGENXBIO had $251 million in cash and expects this to fund operations into late Q4 2027. The company recorded a net loss of $40.7 million for Q3 but gained $38 million from a litigation settlement. These developments position REGENXBIO to potentially launch new gene therapies in 2027 and 2028.
REGENXBIO's Q3 2026 financial results and operational highlights provide context for readers following biotech developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health stocks tradable on Pluang, 94 rose and 48 fell. Notable movers include ADMA Biologics Inc (ADMA) up 19.56% at USD 12.53 with 100% sell orders, Revolution Medicines Inc. (RVMD) up 7.14% at USD 213.95, and Becton Dickinson and Co (BDX) down 6.86% at USD 194.84 with 100% sell orders. The most notable figure is ADMA's 19.56% gain.
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
ACM Research reported a 37% year-over-year revenue increase to $367.7 million in Q3 2026, driven by strong demand in electrochemical plating (ECP) and advanced packaging technologies. The company is expanding manufacturing capacity and global sales e...
Purple has renewed its partnership with Lucid Motors to continue providing WiFi services across Lucid's operations in Riyadh. This renewal ensures that both staff and visitors have secure and easy internet access, supporting Lucid's growing presence ...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed public dealings involving the purchase and sale of 118,333 ordinary shares each on November 4, 2026. The transactions were conducted within a price range of 295 to 304 per share. Ther...
